Judged Worse Than Not Losing Weight

Researchers gave 607 people a short description of a stranger and asked what they thought of them. The descriptions were identical except for one detail: how the person had lost weight. The version who had used a GLP-1 was judged more harshly than the version who had dieted — and more harshly than the version who had not lost weight at all.^[1]

What was done

Two randomized experiments, each with participants reading a brief history of a fictional person and then completing measures of weight-related stereotyping and willingness to associate with them. What varied between groups was only the weight history.

The penalty for taking the drug exceeded the penalty for the weight.

That last row is the finding. Weight stigma is well documented, and the expectation would be that losing weight reduces it. Here, losing it by this particular route did not merely fail to help — it left the person judged worse than if they had not lost it.

The second experiment locates it precisely

A second experiment with 706 participants added the situation people actually fear: regain. Targets were described as having regained weight after stopping a GLP-1, having regained after stopping a diet and exercise plan, never having lost weight, or having maintained a loss.

• After regain, the GLP-1 and diet-and-exercise targets were judged the same. The extra penalty for the drug disappeared.
• Both were judged worse than the person who maintained their loss (both P ≤ 0.001).

That is a sharper result than “people are judgmental about these drugs,” and it fits what patients report. Our interview-based coverage found stigma emerging as one of eight themes, varying by what the drug had been prescribed for — eight things patients said. This is the experimental counterpart, and it puts a direction and a size on something people described from the inside.

What a vignette study can and cannot show

Stated attitudes and behavior come apart routinely, and usually in the direction of people being better in person than on a questionnaire. It would be a mistake to read this as a measurement of what you will encounter.

The effect sizes also deserve their intervals. The gap against the diet-and-exercise target was 0.52 with an interval from 0.27 to 0.76 — solid. The gap against the no weight loss target, which is the striking one, was 0.26 with an interval from 0.02 to 0.51. That barely excludes zero, and the scale it sits on is not stated in the abstract. It is the most interesting finding here and the least firmly established.

Why it is worth knowing anyway

Because it names something people are told they are imagining. A patient who senses that disclosing this medication costs them something is not being oversensitive — there is experimental evidence that the disclosure changes how they are evaluated, in the direction they suspect.

It also bears on a practical decision this register sees constantly: whether to tell anyone. There are good clinical reasons to disclose — a medication missing from your record is invisible to interaction checking and to the team preparing a procedure, which we set out in what your doctor cannot see. Those reasons do not disappear because disclosure carries a social cost, and pretending the cost is not there helps nobody.

The authors’ own conclusion is that stigma follows people across the whole cycle of losing and regaining, and that stigma-reduction efforts belong in weight management. That is a reasonable thing to conclude from two experiments with fictional targets, stated at about the right strength.